Key result
Patients with primary cardiac lymphoma treated with systemic chemotherapy and post-chemotherapeutic radiation therapy had a longer median progression-free survival compared to those treated with chemotherapy alone (41.0 vs. 12.0 months).
Why the study?
Does systemic chemotherapy (R-CHOP) combined with radiation therapy provide long-term disease-free survival in a patient with primary cardiac lymphoma?
Population
59-year-old man with primary cardiac lymphoma presenting with chest pain, with no evidence of extracardiac…
Design
Case_report
Follow-up
over 4 years
Authors
Loading...
Suggests potential benefit of adding radiation after chemotherapy in primary cardiac lymphoma; leaves open validation in prospective trials with attention to late cardiac toxicity.
Case Report (n=13)
Does systemic chemotherapy (R-CHOP) combined with radiation therapy provide long-term disease-free survival in a patient with primary cardiac lymphoma?
Absolute Event Rate: 41% vs 12%
While R-CHOP chemotherapy and radiation therapy can achieve long-term disease-free survival in primary cardiac lymphoma, clinicians must remain vigilant for delayed, severe radiation-induced cardiac complications.
Shin et al. (2010) conducted a case report in Primary cardiac lymphoma (n=13). Systemic chemotherapy and post-chemotherapeutic radiation therapy vs. Systemic chemotherapy alone was evaluated on Median progression-free survival (months). Patients with primary cardiac lymphoma treated with systemic chemotherapy and post-chemotherapeutic radiation therapy had a longer median progression-free survival compared to those treated with chemotherapy alone (41.0 vs. 12.0 months).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: